A rigorous randomized clinical trial of rizatriptan conducted by UCLA and Mayo Clinic researchers failed to outperform ...

Compared with placebo, rizatriptan does not alleviate symptoms of vestibular migraine attacks at 1 hour and shows minimal ...

Moebius syndrome is a rare condition that affects several cranial nerves, impairing the muscles that control facial ...

Tom Nolan reviews this week’s research Giving a hearing aid to people with untreated hearing loss helps them retain one additional person in their social network over a three year period. This catchy ...

A recent study found that nearly 1 in 10 people with multisite pain in a representative sample of Japan’s population met ...

If you have symptoms of irritable bowel syndrome (IBS) and migraine but are trying to “tough it out” without a diagnosis or treatment plan, it’s time to reconsider. “Even though these ...

Click Therapeutics' digital therapeutic (DTx) CT-132 has been approved by the FDA, becoming the first treatment of its type in the US for preventing attacks in people with episodic migraine.

AbbVie’s Aquipta has become the first once-daily oral therapy for both chronic and episodic migraine prevention to be recommended by NICE for NHS patients in England and Wales. Final draft ...

HSSC CET Eligibility Criteria 2025: The Haryana Staff Selection Commission has issued an official notification for the Haryana Common Entrance Test (CET) 2025, outlining the eligibility criteria.

The PDF on this page is not automatically displayed on smaller devices.